Searches for the so-called “Wolverine Stack” have climbed 948% in a year, and 2.8 million people a month are Googling a drug that isn’t approved anywhere in the world. These statistics are astounding. Longevity Live looks at what peptides actually are, what is driving the boom — and why a “99% purity” claim on a vial tells you far less than you think.
Has The Peptide Search Boom Outrun The Science?
Peptides have moved from niche research forums and elite sports circles into ordinary conversation. They are discussed on podcasts, demonstrated on TikTok, sold on Instagram and debated in gym changing rooms. At Longevity Live we have been tracking this shift for well over a year, and the pace of it now concerns us.
We received a new search analysis by Licensed Peptides, a UK-based research peptide supplier, which shows demand for the world’s most-searched peptides has multiplied over the past twelve months. This prompted this post. Like many others in the longevity industry, we’ve been watching the marketing mania around peptides – and it has been fascinating, but also concerning.
The figures that show the interest
According to Licensed Peptides, searches for the “Wolverine Stack” — a combination of BPC-157 and TB-500, nicknamed after the Marvel character for its association with tissue-repair research — have risen 948%, to 21,000 searches a month.
| Peptide / search term | Monthly Google searches | Annual growth |
| Retatrutide | 2.8 million | 979% |
| BPC-157 | 456,000 | 572% |
| Semax | 251,000 | 549% |
| TB-500 | 199,000 | 876% |
| CJC-1295 | 176,000 | 1,041% |
| GHK-Cu (copper peptide) | 51,000 | 6,407% |
| “Wolverine Stack” | 21,000 | 948% |
Source: Licensed Peptides search analysis, 12-month change to mid-2026. Licensed Peptides is a commercial supplier of research peptides; Longevity Live publishes the figures as an indicator of public interest, not as an endorsement of any supplier.
What Does No Approval Mean
Read that table again with one fact in mind: not a single compound on it is an approved medicine. Retatrutide, the most-searched of the group at 2.8 million queries a month, is an investigational Eli Lilly drug still in Phase 3 trials. It cannot legally be bought, prescribed or compounded anywhere in the world. Lilly has said it expects to file for FDA approval in the first quarter of 2027, which means a licensed product is unlikely before late 2027 at the earliest.
In other words, millions of people every month are searching for compounds they cannot legally obtain through a pharmacy. Yet a market has grown to meet them anyway.
What a peptide actually is
A peptide is a short chain of amino acids — the same building blocks that make up proteins. The line between a peptide and a protein is essentially one of length: chains of roughly two to fifty amino acids are called peptides, and longer chains are called proteins. Nothing more exotic than that.
Did you know your body makes thousands of them? They work as signaling molecules, binding to specific receptors and instructing cells to do particular things. Insulin is a peptide. So are oxytocin, glucagon, ghrelin, vasopressin and the hormones that govern appetite, growth and reproduction.
That specificity is exactly why the pharmaceutical industry has pursued peptides for a century. Insulin, first used in a patient in 1922, was among the earliest. More than a hundred peptide medicines are approved today, including semaglutide and tirzepatide for diabetes and obesity, teriparatide for osteoporosis, desmopressin for diabetes insipidus, and the GnRH analogues used in fertility treatment and cancer care.
“Peptide” is a description of chemistry, not a claim about safety. This is a point many are missing, or ignoring intentionally.
It tells you what a molecule is built from. It tells you nothing whatsoever about whether that molecule has ever been tested in a human being, at what dose, or with what consequences.
Three very different categories, routinely blurred
Wouldn’t you want to know that whatever you put into your body, has been checked and is safe for use? We think this is an important consideration, and have outlined here how to navigate the current status of peptide medicines.
Approved peptide medicines
They have completed clinical trials, carry a licence from a regulator, are made under pharmaceutical manufacturing standards, and are dispensed against a prescription with known dosing and a known side-effect profile.
Investigational peptides
Currently in clinical trials, with genuine human data accumulating, but not yet approved. Retatrutide sits here. Legally, the only way to access it is to enroll in a trial.
Research chemicals
BPC-157, TB-500, CJC-1295, Semax, GHK-Cu and most of the rest. These are sold labelled “for research use only — not for human consumption.” That phrase is the entire legal architecture of the market. It allows a compound to be sold outside medicines regulation, and with it, outside any obligation to meet pharmaceutical manufacturing, testing or labelling standards.
Everyone involved understands that a meaningful share of “research use only” product ends up in a human. The label is a liability shield, not a description of what happens next.
What the “Wolverine Stack” is, and what’s actually known about it
One of the more popular compounds that consumers seem to be happy to take regardless of safety is the Wolverine Stack. BPC-157 is a synthetic peptide based on a sequence identified in human gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in cell migration, blood vessel formation and wound repair. Combined, they have acquired a reputation online for accelerating recovery from soft-tissue injury.
The evidence behind that reputation is thinner than the enthusiasm suggests. Almost all of it comes from rodent studies and cell cultures.
No completed human trials
There are no completed large-scale human trials of either compound, no established human dosing, and no long-term human safety data at all. Absence of evidence is not evidence of harm — but it is not evidence of safety either, and it is the latter that people are assuming.
What you need to consider
One open question deserves particular mention. Both compounds are understood to influence angiogenesis, the formation of new blood vessels. That mechanism is plausibly useful in healing tissue. Its effect on an undiagnosed tumor is unknown.
Researchers have raised the theoretical concern; nobody has resolved it in either direction. Anyone who tells you confidently that these compounds are safe is telling you something the data does not support.
For competitive athletes there is no ambiguity at all. BPC-157 has been on the World Anti-Doping Agency prohibited list since 2022 under the S0 unapproved substances category. TB-500 and thymosin beta-4 derivatives are prohibited at all times, as are growth hormone secretagogues such as CJC-1295 and ipamorelin. Athletes have received four-year bans for exactly these compounds.
The regulatory picture is shifting — and being misread
In late 2023 the US Food and Drug Administration placed BPC-157 and eighteen other peptides on its Category 2 bulk drug substances list, citing safety concerns including immunogenicity and an absence of human clinical data. That effectively barred compounding pharmacies from preparing them.
That position has been in motion through 2026. In February, Health and Human Services Secretary Robert F. Kennedy Jr. announced that most of the nineteen Category 2 peptides would be considered for reclassification. In April, twelve were formally removed from Category 2 following the withdrawal of their nominations, BPC-157 among them.
Illegal is not the same as becoming legal
The FDA’s Pharmacy Compounding Advisory Committee began reviewing individual substances from July. This has been widely reported online as peptides “becoming legal,” and that reading is wrong in a way that matters. Removal from Category 2 is not approval. It does not confer Category 1 status automatically — each substance still requires individual advisory committee review.
FDA scientists remain unconvinced of peptide safety and benefits
Panel members with backgrounds in academia, rather than peptides, mostly voted against the substances, which are widely advertised on social media.
None of these compounds has completed clinical trials. None is an FDA-approved medicine.
What has changed is a restriction on regulated compounding pharmacies operating under prescription; what has not changed is the evidence base, or the status of anything bought from an unregulated website.
Enforcement has intensified in parallel
Regulators are not treating this as a settled market. For example in the UK, the Medicines and Healthcare products Regulatory Agency seized almost 2,000 doses of suspected illegal weight-loss and peptide products during February 2026 raids on sites in Lincolnshire and Nottinghamshire.
In May, in its largest seizure of unlicensed weight-loss medicines to date, the MHRA recovered around 12,000 doses from a property near Northampton and arrested two men on suspicion of offences under the Human Medicines Regulations 2012. Across 2025 the agency’s Criminal
Enforcement Unit seized close to 20 million doses of illegally traded medicines with a street value of roughly £45 million, and worked with internet service providers to disrupt more than 1,500 websites and social media accounts marketing illegal products to the public.
The FDA has continued its own enforcement against companies selling unapproved injectable peptides online.
Fifteen hundred websites is not a fringe problem. It is an industry.
What can actually go wrong
When something is bought outside the regulated supply chain, the buyer inherits every risk the system would normally absorb. These are the failure modes, in rough order of how often they appear.
The vial contains the wrong amount
Peptides are dosed in micrograms and milligrams. A vial containing substantially less active compound than the label claims is a waste of money. One containing substantially more is a dosing error waiting to happen, and the buyer has no way of detecting either.
The vial contains the wrong compound
Without independent identity confirmation — typically mass spectrometry — there’s no way to know that the powder is the peptide named on the label rather than a related compound, a degraded one, or something else entirely. A professional-looking vial with a crisp label is a printing decision, not a testing result.
Contamination and sterility failures
This is the risk that receives the least attention and deserves the most. Bacterial endotoxins are fragments of bacterial cell walls that survive sterilization and can cause fever, inflammation and, at sufficient dose, serious systemic reactions.
They’re invisible, and they are not detected by purity testing. Products made outside sterile manufacturing conditions, or reconstituted at home with non-sterile water and poor technique, carry real infection risk — abscesses, cellulitis and bloodstream infections among them.
Nobody is watching for side effects
Approved medicines sit inside a pharmacovigilance system: adverse events are reported, aggregated and acted on. A compound bought from a website sits outside that entirely. If it harms you, no one records it, no pattern is detected, and the next buyer learns nothing.
Interactions and pre-existing conditions are unmapped
Because these compounds have not been through clinical trials, there’s no meaningful data on how they interact with prescription medicines, or on how they behave in people with cancer, cardiovascular disease, autoimmune conditions or in pregnancy. Self-administering without a clinician’s oversight means nobody is asking those questions.
Legal, financial and sporting exposure
Importing unlicensed medicines carries legal risk that varies by country and is frequently underestimated. For anyone subject to anti-doping testing, use of these compounds means a ban measured in years.
Why “99% purity” is not the reassurance it appears to be
The single most common misunderstanding in this market concerns testing. A certificate stating “99% purity” is widely read as confirmation that a product has been thoroughly checked. It confirms one narrow thing.
Dr Samuel Sarmiento of Licensed Peptides, speaking to the growth in demand his company’s data has tracked, argues the risk lies precisely in that gap between what buyers assume and what a purity figure measures.
“People often assume that a purity percentage tells the whole story. It doesn’t. A product can have a high purity result while still failing to answer other important questions — whether it contains the correct quantity of the compound, whether its identity has been independently confirmed, or whether it has been screened for endotoxins and sterility where appropriate.”
“A counterfeit or poorly manufactured peptide doesn’t have to contain an obviously dangerous substance to create problems. It could contain less active ingredient than advertised, significantly more than expected, a completely different compound, or contamination introduced during manufacturing. The biggest misconception is that a professional-looking vial automatically means the contents have been properly verified.”
Verification, transparency, and safety
Comprehensive verification, on his account, covers six separate questions: the identity of the peptide, the quantity present, chemical purity, sterility, endotoxin levels and visual quality. A purity percentage answers one of them.
Sarmiento is a commercial supplier and has an obvious interest in buyers scrutinising quality control. The substance of the point stands independently of that: purity and safety are not the same measurement, and treating them as interchangeable is how people get hurt.
“Transparency shouldn’t be viewed as a marketing feature. Researchers deserve to know exactly how a batch has been tested, which laboratory carried out the testing, and what those results actually demonstrate.”
If you’re going to look at this market anyway
Longevity Live’s position is that these compounds belong in clinical research and in the hands of a qualified clinician, not in an online shopping basket. But we also recognize that people are buying them regardless, and that a refusal to engage helps nobody.
If you’re assessing a supplier, these are the questions that separate a serious operation from a marketing website.
- Is there a batch-specific Certificate of Analysis — tied to the exact lot number on your vial, not a generic sample document reused across every product?
- Was the testing carried out by an accredited independent laboratory, named on the certificate, rather than by the seller?
- Does the testing cover identity (mass spectrometry) and quantity, or only purity by HPLC?
- Has the batch been screened for endotoxins and sterility?
- Is the manufacturing location and process disclosed?
- Will the seller answer direct questions about quality control, or does the conversation stop at the purity figure?
Consult a Specialist
And the question that precedes all of them: have you discussed this with a doctor who knows your medical history?
For anyone with a cancer history, an autoimmune condition, cardiovascular disease, or who is pregnant, trying to conceive or subject to anti-doping rules, that conversation is not optional.
In closing
A 948% increase in searches for the Wolverine Stack in twelve months is a striking number, but it’s also a measure of curiosity, not of evidence. The science behind BPC-157 and TB-500 has not advanced 948% in that period. It has barely advanced at all.
The gap between what is known about these compounds and what is being claimed about them online is now enormous, and it is being filled by people with something to sell. Regulators are seizing product by the tens of thousands of doses and shutting down websites by the thousand.
That is what a market moving faster than its evidence base looks like.
The value of peptides
We want to make it clear, that despite our reservations around safety, peptides are a genuinely important class of medicine and will produce more real therapies in the years ahead. That’s precisely why the current free-for-all is worth taking seriously: the compounds that turn out to work deserve better than a reputation built in an unregulated market, and the people buying them deserve to know what is actually in the vial.
There is a clear disconnect between the marketing claims and the clinical evidence for unregulated peptides. We don’t know the long-term risks, and as we have shown, there’s no rigorous data to support their safety and efficacy in humans.
When you buy these products from the black or gray market, you should be concerned about product quality, contamination, and unregulated supply chains. A lot of these products are mislabeled and contaminated. There are potential risks and adverse effects which can compromise your health. Impact your heart, create issues of insulin sensitivity and even result in mental instability. Ultimately, if you do not know how much you’re taking, or if the product is contaminated, it could harm you, or even prove fatal.
We look forward to more research and the subsequent regulatory approval of peptides. Until then, you have to ask, knowing the facts right now, is whether the risk is worth it. Or not?
Editors note
This article is for information only and is not medical advice. None of the compounds discussed is an approved medicine, and Longevity Live does not endorse their use. Speak to a qualified healthcare professional before taking any substance, particularly an injectable one.
References
Licensed Peptides search analysis: https://licensedpeptides.com/
World Anti-doping Banned List: https://www.uefa.com/news-media/news/0270-13e6c3db6ce4-833846d06070-1000–wada-unveils-2022-prohibited-list-of-banned-substances-a/
FDA bulk drug substances Category 2 listings and 2026 reclassification actions: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
MHRA enforcement announcements, 2025–2026: https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
WADA Prohibited List; Eli Lilly clinical trial disclosures: https://www.wada-ama.org/en/prohibited-list
FDA Gov: https://www.fda.gov/media/94155/download
PBS: https://www.pbs.org/newshour/health/watch-live-fda-advisory-panel-considers-use-of-peptides
Photo credit: Cottonbro studio
Editorial Declaration: This article was compiled with assistance from Claude.ai
![women [longevity live]](https://longevitylive.com/wp-content/uploads/2020/01/photo-of-women-walking-down-the-street-1116984-100x100.jpg)
